RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
Neusignal Therapeutics is a medical company focused on developing therapeutic medicines for dementia and various psychiatric illnesses. The company specializes in the research and development of small molecule drugs aimed at addressing brain diseases and overcoming challenges associated with central nervous system disorders. By concentrating on innovative therapeutic agents, Neusignal Therapeutics seeks to improve the quality of life for patients suffering from these conditions, aiming to resolve a range of issues related to brain health.
Medii, Ltd. is a Tokyo-based company that specializes in developing an e-consulting platform aimed at addressing the shortage of medical specialists in community healthcare. Founded in 2020, Medii offers online specialist consultation services that facilitate medical treatment through e-consulting and e-opinion. The platform helps to eliminate clinical questions and concerns by providing on-site consulting to medical institutions, leveraging the expertise of experienced doctors. This approach enables clinics and patients to access necessary medical assistance in areas where specialist resources are limited.
A10 Lab is a company that aims to makes people happy with technology that is independent of Sony's new business creation program. It provides Google Play an app that allows users to do things that they have never been able to do with the custom app 'Min Chale' selected for two consecutive years. It is a company that brings profits to companies by improving lifetime value (sales) through the habitation of users that companies have.
Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.
CellFiber Co., Ltd., founded in 2015 and headquartered in Tokyo, Japan, specializes in the research, development, production, and sale of cell-laden soft materials. The company focuses on cell culture technology and offers support tools for drug discovery, primarily aimed at biopharmaceutical development. CellFiber has developed a unique cell culture platform technology that facilitates efficient bio-manufacturing solutions, enhancing cell and gene therapy applications. This technology aims to increase yields and product quality while ensuring the stability, predictability, reproducibility, and scalability of cell production. By streamlining the mass production process of cells, CellFiber enables clients to reduce costs and timelines, ultimately supporting their transition from research to clinical use.
AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.
Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.
Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.
Varinos Inc. is a clinical testing company based in Tokyo, Japan, founded in 2017. It specializes in genomic testing and continuous clinical sequencing services, offering innovative solutions such as endometrial microbiome testing and the analysis of intrauterine flora. By leveraging next-generation sequencing technology, Varinos partners with medical institutions to provide advanced contract analysis services. The company's genome analysis technology enables the detection of microscopic amounts of bacteria, facilitating the examination and diagnosis of genetic abnormalities in embryos prior to pregnancy. This approach aims to alleviate both physical and mental burdens for women seeking reproductive health solutions.
reverSASP Therapeutics is focused on developing innovative drugs aimed at treating aging-related diseases by targeting senescent cells. The company leverages its deep understanding of the biology underlying these conditions, particularly the Senescence-associated secretory phenotype (SASP), to create therapeutic solutions. By addressing the challenges posed by declining birthrates and an aging population, reverSASP Therapeutics aims to extend healthy life expectancy and improve the quality of life for older individuals. Its research emphasizes the unique properties of inflammatory senescent cells, which are linked to various age-related diseases, positioning the company as a key player in the field of longevity and healthspan enhancement.
mediPhone is a provider of telephone medical interpreter and video medical interpreter service intended to eliminate language barriers in medical care. The company's services include medical translation app, dispatch of medical interpreter to advanced treatment and medical checkup, medical certificate, consent form, hospitalization guidance, in-hospital, enabling clients to access healthcare services without facing language barrier issues in regions of their choices in a convenient manner
LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.
Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.
Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.
A10 Lab is a company that aims to makes people happy with technology that is independent of Sony's new business creation program. It provides Google Play an app that allows users to do things that they have never been able to do with the custom app 'Min Chale' selected for two consecutive years. It is a company that brings profits to companies by improving lifetime value (sales) through the habitation of users that companies have.
Fast Doctor is a medical consultation service that specializes in providing after-hours support for emergency visits. The company enables patients to access essential emergency care during nights and holidays, offering services such as triage, medical examinations, prescriptions, and home settlement. By facilitating prompt access to emergency medical services, Fast Doctor helps alleviate pressure on ambulance and emergency care systems, ensuring that patients receive timely assistance when they need it most.
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.
RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.
LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.
Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.
Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.
AccRna, Inc.'s aim is to promote therapeutic innovation in the form of nucleic acid medicine utilizing our robust DDS platform, providing effective treatment for refractory diseases for which there is currently no cure. Our dream is to deliver a “radical cure” to patients suffering from refractory diseases all over the world by safely and efficiently achieving the ultimate in the therapy utilizing nucleic acid.
Fast Doctor is a medical consultation service that specializes in providing after-hours support for emergency visits. The company enables patients to access essential emergency care during nights and holidays, offering services such as triage, medical examinations, prescriptions, and home settlement. By facilitating prompt access to emergency medical services, Fast Doctor helps alleviate pressure on ambulance and emergency care systems, ensuring that patients receive timely assistance when they need it most.
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.
RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.
EdiGENE Japan, now known as Modalis Therapeutics Corporation, is a biotechnology company based in Tokyo that focuses on developing innovative therapies for serious genetic disorders. Founded in 2016, the company leverages its proprietary CRISPR-GNDM technology, which allows for precise modulation of gene expression and histone modification without the need for traditional gene editing methods. Modalis Therapeutics aims to address unmet medical needs related to orphan genetic diseases, building a robust intellectual property portfolio in collaboration with the University of Tokyo.
Veldt offer wearable products, IoT products and services under the VELDT brand with a clear concept and functional design. The first product we launched was a smart watch, VELDT SERENDIPITY. Their design concept of regaining the excess time spent on your smartphone, in order to spend it looking around and discovering something new, has received positive appraisals worldwide.
PENTAS Inc., founded in 2015 and based in Tokyo, Japan, specializes in the development of medical analysis software and devices. The company focuses on creating innovative solutions for medical equipment, particularly in the area of cerebral aneurysm fluid analysis and intracranial stents. As a subsidiary of Allm Inc., PENTAS is dedicated to advancing medical technology to improve patient outcomes.
mediPhone is a provider of telephone medical interpreter and video medical interpreter service intended to eliminate language barriers in medical care. The company's services include medical translation app, dispatch of medical interpreter to advanced treatment and medical checkup, medical certificate, consent form, hospitalization guidance, in-hospital, enabling clients to access healthcare services without facing language barrier issues in regions of their choices in a convenient manner
Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.
Yukashikado Inc. is a Tokyo-based company founded in 2013 that specializes in personal nutrition testing products. The company offers at-home nutrition testing solutions that analyze various nutrients, including proteins, vitamins, minerals, and oxidative stress, using urine samples. These tests allow individuals to evaluate nutritional deficiencies and excesses, with results accessible through personal computers and smartphones. By providing an easy way to monitor nutritional intake and improvements, Yukashikado supports individuals in managing their health through personalized nutrition. The company sells its products online, catering to a growing demand for accessible health monitoring tools.
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.
HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.
RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.
CellBank is a facility that stores cells with a specific genome for use in a product or for medicinal purposes in the future. Their company offers regenerative medicines. The medical community receives technology and services efficiently, free from the constraints of medical customs and common sense.
NB Health Laboratory is a biotechnology company specializing in the research and development of innovative new drugs centering on respiratory diseases, chronic inflammation and infectious diseases.
AccRna, Inc.'s aim is to promote therapeutic innovation in the form of nucleic acid medicine utilizing our robust DDS platform, providing effective treatment for refractory diseases for which there is currently no cure. Our dream is to deliver a “radical cure” to patients suffering from refractory diseases all over the world by safely and efficiently achieving the ultimate in the therapy utilizing nucleic acid.
EdiGENE Japan, now known as Modalis Therapeutics Corporation, is a biotechnology company based in Tokyo that focuses on developing innovative therapies for serious genetic disorders. Founded in 2016, the company leverages its proprietary CRISPR-GNDM technology, which allows for precise modulation of gene expression and histone modification without the need for traditional gene editing methods. Modalis Therapeutics aims to address unmet medical needs related to orphan genetic diseases, building a robust intellectual property portfolio in collaboration with the University of Tokyo.
Veldt offer wearable products, IoT products and services under the VELDT brand with a clear concept and functional design. The first product we launched was a smart watch, VELDT SERENDIPITY. Their design concept of regaining the excess time spent on your smartphone, in order to spend it looking around and discovering something new, has received positive appraisals worldwide.
Veldt offer wearable products, IoT products and services under the VELDT brand with a clear concept and functional design. The first product we launched was a smart watch, VELDT SERENDIPITY. Their design concept of regaining the excess time spent on your smartphone, in order to spend it looking around and discovering something new, has received positive appraisals worldwide.
EdiGENE Japan, now known as Modalis Therapeutics Corporation, is a biotechnology company based in Tokyo that focuses on developing innovative therapies for serious genetic disorders. Founded in 2016, the company leverages its proprietary CRISPR-GNDM technology, which allows for precise modulation of gene expression and histone modification without the need for traditional gene editing methods. Modalis Therapeutics aims to address unmet medical needs related to orphan genetic diseases, building a robust intellectual property portfolio in collaboration with the University of Tokyo.
HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.
Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.
NIL is a bio-tech company that develops innovative and functional ultrafine particle technology based on many years of research experience.
NIL provides services including planning, development, maintenance, and sales of various software development tools, research and development linked to software engineering, and more. It also offers services like system and software development, maintenance, sales, and consultation. It offers software tools for use with things like automotive and medical systems.
ReasonWhy Inc. is a Japan-based company founded on July 7, 2011, that specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online second-opinion service that connects patients with doctors from the Whytlink network; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers in Japan; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy seeks to enhance communication and information sharing within the medical community while improving patient access to healthcare resources.
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
NB Health Laboratory is a biotechnology company specializing in the research and development of innovative new drugs centering on respiratory diseases, chronic inflammation and infectious diseases.
ReasonWhy Inc. is a Japan-based company founded on July 7, 2011, that specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online second-opinion service that connects patients with doctors from the Whytlink network; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers in Japan; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy seeks to enhance communication and information sharing within the medical community while improving patient access to healthcare resources.
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
AccRna, Inc.'s aim is to promote therapeutic innovation in the form of nucleic acid medicine utilizing our robust DDS platform, providing effective treatment for refractory diseases for which there is currently no cure. Our dream is to deliver a “radical cure” to patients suffering from refractory diseases all over the world by safely and efficiently achieving the ultimate in the therapy utilizing nucleic acid.
PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.
CellSeed Inc. is a biotechnology company based in Tokyo, Japan, focused on developing regenerative medicine products primarily for markets in Japan and Europe. Founded in 2001, the company specializes in cell-sheet regenerative medicines, which include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart diseases, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for treating osteoarthritis. In addition to its product offerings, CellSeed also provides temperature-responsive cultureware, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company further supports the industry through contract development and manufacturing services.
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.
ProbeX specializes in the development, manufacture, and distribution of molecular imaging technology. The company focuses on creating research tools that enhance molecular imaging capabilities, particularly in the context of drug discovery. In addition to its product offerings, ProbeX provides consulting services to support research initiatives in the field of molecular imaging. Through its innovative approach, ProbeX aims to advance the understanding of biological processes and improve outcomes in pharmaceutical research.
CellSeed Inc. is a biotechnology company based in Tokyo, Japan, focused on developing regenerative medicine products primarily for markets in Japan and Europe. Founded in 2001, the company specializes in cell-sheet regenerative medicines, which include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart diseases, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for treating osteoarthritis. In addition to its product offerings, CellSeed also provides temperature-responsive cultureware, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company further supports the industry through contract development and manufacturing services.
Chiome Bioscience Inc. is a Japanese biotechnology company founded in 2005, specializing in drug discovery and development through its proprietary ADLib® antibody generation technology. The company focuses on providing various services, including protein expression and purification, stable cell line generation, and antibody generation using its platform or B cell cloning techniques. Chiome's product pipeline features several therapeutic antibodies targeting conditions such as liver cancer, lung cancer, malignant mesothelioma, and diabetic macular edema. The company collaborates with universities, research institutions, and pharmaceutical firms, enhancing its research capabilities through partnerships, including a collaboration with Velabs Therapeutics to discover functional antibodies. In 2017, Chiome reorganized its management and shifted its strategic focus from platform development to drug discovery, establishing a clinical function to support this transition. The company also engages in technology licensing and joint research initiatives, aiming to advance its therapeutic offerings and corporate value.